Integrity Financial’s AbCellera Biologics ABCL Stock Holding History

Integrity Financial’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$34.9K	–	293
2026 Q1	$34.9K	Hold	10,000	–	–	0.02%	218
2025 Q4	$34.2K	Sell	10,000 -50	-0.5%	-$223	0.02%	215
2025 Q3	$50.6K	Hold	10,050	–	–	0.02%	199
2025 Q2	$34.5K	Sell	10,050 -2,000	-17%	-$4.98K	0.02%	211
2025 Q1	$26.9K	Hold	12,050	–	–	0.02%	203
2024 Q4	$35.3K	Hold	12,050	–	–	0.02%	181
2024 Q3	$31.3K	Hold	12,050	–	–	0.02%	172
2024 Q2	$35.7K	Hold	12,050	–	–	0.02%	167
2024 Q1	$54.6K	Hold	12,050	–	–	0.04%	150
2023 Q4	$68.8K	Sell	12,050 -1,000	-8%	-$4.63K	0.05%	136
2023 Q3	$60K	Buy	+13,050	New	+$79.4K	0.05%	137

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Integrity Financial's ABCL Position: Q2 2026 in Review

Integrity Financial sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 10,000 shares — an estimated $34.9K sold.

Integrity Financial first reported a position in ABCL in Q3 2023 and held it in 11 quarters. The position peaked at $68.8K in Q4 2023. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Integrity Financial reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Integrity Financial sold 10,000 AbCellera Biologics shares in Q2 2026, an estimated $34.9K.
Integrity Financial first reported a position in AbCellera Biologics in Q3 2023 and held it in 11 quarters.
Integrity Financial's AbCellera Biologics position peaked at $68.8K in Q4 2023.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Integrity Financial's 13F filing for Q2 2026, filed 31 Jul 2026.